Sugi Predict

Sugi Predict / Compounds / SCHEMBL5524713

SCHEMBL5524713

SCHEMBL5524713

CCn1c2ccccc2c2nc3ccccc3nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 1.00
▸ TSHR P16473 7/20 1.00
▸ CASP1 P29466 5/20 1.00
▸ CASP7 P55210 5/20 1.00
▸ ALDH1A1 P00352 5/20 1.00
▸ L3MBTL1 Q9Y468 4/20 1.00
▸ HSD17B10 Q99714 4/20 1.00
▸ KDM4E B2RXH2 4/20 1.00
▸ USP2 O75604 3/20 1.00
▸ NPC1 O15118 2/20 1.00
▸ HCRTR1 O43613 1/20 1.00
▸ TP53 P04637 1/20 1.00
▸ TDP1 Q9NUW8 4/20 0.77
▸ POLB P06746 4/20 0.77
▸ MAPK1 P28482 4/20 0.77
▸ LMNA P02545 2/20 0.77
▸ ALOX15 P16050 1/20 0.77
▸ KMT2A Q03164 6/20 0.71
▸ MEN1 O00255 4/20 0.71
▸ GLA P06280 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5530202 0.87 TSHR (1.00) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL5527836 0.84 TSHR (0.83) MAPTTSHRCASP1CASP7ALDH1A1
Dimethylamine SCHEMBL1581069 0.84 MAPT (0.71) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL5522487 0.82 TSHR (0.69) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL13165173 0.82 MAPT (0.71) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL13889180 0.81 POLB (1.00) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL15289657 0.80 TSHR (0.72) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL9706282 0.80 TSHR (0.72) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL20147874 0.80 CTNNB1 (0.67) MAPTTSHRCASP1CASP7ALDH1A1
SCHEMBL9706276 0.80 POLB (0.75) MAPTTSHRCASP1CASP7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158247-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors OMEROS CORPORATION 2016-06-09 — — US disclosed
US-20160015715-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS OMEROS CORPORATION 2016-01-21 — — US disclosed
US-9220715-B2 Treatment of addiction and impulse-control disorders using PDE7 inhibitors OMEROS CORPORATION (US) 2015-12-29 — — US disclosed
US-9119822-B2 Use of PDE7 inhibitors for the treatment of movement disorders OMEROS CORPORATION (US) 2015-09-01 — — US disclosed
US-20140179717-A1 Use of PDE7 Inhibitors for the Treatment of Movement Disorders OMEROS CORPORATION (US) 2014-06-26 — — US disclosed
US-8637528-B2 Use of PDE7 inhibitors for the treatment of movement disorders OMEROS CORPORATION (US) 2014-01-28 — — US disclosed
US-20130267502-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors OMEROS CORPORATION 2013-10-10 — — US disclosed
US-20120115849-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors OMEROS CORPORATION 2012-05-10 — — US disclosed
US-20110303901-A1 6H-INDOLO[2,3-b]QUINOXALINE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODE USING THE SAME NATIONAL TSING HUA UNIVERSITY (TW) 2011-12-15 — — US disclosed
US-20100227853-A1 INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES TRUSTEES OF BOSTON COLLEGE (US) 2010-09-09 — — US disclosed
US-20100227853-A1 INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES TRUSTEES OF BOSTON COLLEGE (US) 2010-09-09 — — US disclosed
US-20100179158-A1 INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-07-15 — — US disclosed
US-20100113486-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS OMEROS CORPORATION (US) 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115849-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors PDE7B, PDE4C, PDE4A MAPT 3149/4885TSHR 1528/4885CASP1 3578/4885
US-20160158247-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors PDE7B, PDE4C, PDE4A MAPT 3149/4885TSHR 1528/4885CASP1 3578/4885
US-20160015715-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS PARK7, PDE7B, PDE7A MAPT 1951/4885TSHR 2222/4885CASP1 4458/4885
US-20140179717-A1 Use of PDE7 Inhibitors for the Treatment of Movement Disorders PARK7, PDE7B, PDE7A MAPT 1951/4885TSHR 2222/4885CASP1 4458/4885
US-20100227853-A1 INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES PDE7A, PDE4A, PDE4C MAPT 3911/4885TSHR 4049/4885CASP1 3830/4885
US-20130267502-A1 Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors PDE7B, PDE4C, PDE4A MAPT 3149/4885TSHR 1528/4885CASP1 3578/4885
US-20110303901-A1 6H-INDOLO[2,3-b]QUINOXALINE DERIVATIVES AND ORGANIC LIGHT EMITTING DIODE USING THE SAME IDO1, IPO9, IDO2 MAPT 2821/4885TSHR 2300/4885CASP1 3210/4885
US-20100113486-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS PARK7, PDE7B, PDE7A MAPT 1951/4885TSHR 2222/4885CASP1 4458/4885
US-20100179158-A1 INHIBITORS OF CYCLIC AMP PHOSPHODIESTERASES PDE7A, PDE4A, PDE4C MAPT 3911/4885TSHR 4049/4885CASP1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.